This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Calliditas Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

Calliditas Therapeutics has a total shareholder equity of SEK106.8M and total debt of SEK982.5M, which brings its debt-to-equity ratio to 920%. Its total assets and total liabilities are SEK1.7B and SEK1.6B respectively.

Belangrijke informatie

920.0%

Verhouding schuld/eigen vermogen

SEK 982.49m

Schuld

Rente dekkingsratio	n/a
Contant	SEK 797.28m
Aandelen	SEK 106.79m
Totaal verplichtingen	SEK 1.64b
Totaal activa	SEK 1.75b

Recente financiële gezondheidsupdates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: CALT's short term assets (SEK1.2B) exceed its short term liabilities (SEK429.8M).

Langlopende schulden: CALT's short term assets (SEK1.2B) do not cover its long term liabilities (SEK1.2B).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: CALT's net debt to equity ratio (173.4%) is considered high.

Schuld verminderen: CALT's debt to equity ratio has increased from 0% to 920% over the past 5 years.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: CALT has sufficient cash runway for more than 3 years based on its current free cash flow.

Voorspelling contante baan: Insufficient data to determine if CALT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

This company listing is no longer active

Calliditas Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Nasdaq Stockholm Decides to Delist Calliditas Therapeutics

Calliditas Resolves to Apply for Delisting of the Common Shares from Nasdaq Stockholm, ADS from Nasdaq Global Select Market

Asahi Kasei Intends to Promote Delisting of the Shares in Calliditas Therapeutics from Nasdaq Stockholm

Recent updates

Nasdaq Stockholm Decides to Delist Calliditas Therapeutics

Calliditas Therapeutics AB (publ)(OM:CALTX) dropped from OMX Nordic All-Share Index

Calliditas Resolves to Apply for Delisting of the Common Shares from Nasdaq Stockholm, ADS from Nasdaq Global Select Market

Asahi Kasei Intends to Promote Delisting of the Shares in Calliditas Therapeutics from Nasdaq Stockholm

Calliditas Therapeutics AB Announces the European Commission Grant Full Marketing Authorization for Kinpeygo

Calliditas Therapeutics AB Announces Positive Transform Phase 2b Topline Data in Primary Biliary Cholangitis

Calliditas Therapeutics AB (publ) Provides Setanaxib Patent Update

Calliditas Partner Stada Receives Positive Chmp Opinion Recommending Full Approval for Kinpeygo[®] for the Treatment of Iga Nephropathy

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and other shareholders for SEK 11.2 billion.

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and others shareholders for SEK 11.2 billion.

Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics

Calliditas Therapeutics AB (Publ) Reaffirms Earnings Guidance for the Year Ending December 31, 2024

Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib

Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results

Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

Calliditas Therapeutics AB Announces an Additional Seven Year Orphan Drug Exclusivity Period for TARPEYO

Calliditas Therapeutics AB Provides Patent Update

Calliditas Therapeutics AB Provides Preliminary Revenue Guidance for the Full Year 2023

Calliditas Therapeutics AB Announces Full FDA Approval of TARPEYO

Calliditas Therapeutics AB (publ) Receives Notice of Allowance for United States Patent Application Covering TARPEYO

Calliditas Therapeutics AB Announces the Initiation of A Phase 2 Clinical Study to Evaluate Setanaxib in Alport Syndrome

Calliditas Therapeutics AB Presents Additional Data Analyses from NefIgArd Phase 3 Trial at American Society of Nephrology Kidney Week 2023

Calliditas Therapeutics' Nomination Committee Composition for the Agm 2024

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023

Calliditas Therapeutics AB Presents Data from the Nefigard Phase 3 Trial At the 17Th International Symposium on Iga Nephropathy (Iigann) Tokyo 2023

STADA and Calliditas Therapeutics AB Announce Submission of Request to EMA for CHMP to Convert Conditional Marketing Authorization for Kinpeygo to Standard, or Full, Marketing Authorization

Calliditas Therapeutics AB (publ) to Report Q1, 2024 Results on May 16, 2024

Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon®? for the Treatment of IgA Nephropathy

Calliditas Therapeutics AB (publ) announces that FDA Grants Priority Review for Full Approval of Tarpeyo for the Treatment of IgA Nephropathy

Calliditas Therapeutics AB (Publ) Provides Sales Guidance for Year Ending December 31, 2023

Calliditas Therapeutics AB (publ) Announces Supportive Interim Data from Phase 2 Head and Neck Cancer Trial with Lead Nox Inhibitor Candidate, Setanaxib

Calliditas Therapeutics AB Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO

Calliditas Therapeutics AB (publ) Announces Board Changes

Calliditas Therapeutics AB (Publ) Provides Earnings Outlook for the Year Ending December 31, 2023

Calliditas Therapeutics AB (publ) Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA Nephropathy

Calliditas Therapeutics AB (publ) to Report Nine Months, 2023 Results on Nov 16, 2023

Calliditas Therapeutics Announces China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

Calliditas' Partner Everest Medicine's New Drug Application for Nefecon Is Accepted by the China Nmpa

Calliditas Therapeutics AB (Publ) Announces Nomination Committee Composition for the Agm 2023

Calliditas Therapeutics AB (publ) Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO[®] (budesonide) in IgA Nephropathy

Calliditas Therapeutics AB (publ) to Report Q1, 2023 Results on May 17, 2023

Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M

Calliditas Therapeutics AB (publ) Announces European Commission Approves Kinpeygo® for Adults with Primary IgA Nephropathy

Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy

Calliditas Therapeutics AB Announces Executive Appointments

Calliditas Therapeutics AB (Publ) Announces Board Changes

Calliditas Therapeutics AB (Publ) Announces First Patient Randomized in Phase 2 Trial in Head and Neck Cancer

Calliditas Therapeutics AB Launches an Online Patient Platform

Calliditas Therapeutics AB (publ) Updates First Patient Randomized in Pivotal TRANSFORM Study with Setanaxib

FdA Grants Calliditas Therapeutics Accelerated Approval of Tarpeyo™ (Budesonide) to Reduce Proteinuria in Iga Nephropathy

U.S. Food and Drug Administration Extends Calliditas Therapeutics AB (Publ)'s the PDUFA Goal Date for New Drug Application

Calliditas Therapeutics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 324 million.

Calliditas Therapeutics AB Receives FDA Fast Track Designation for setanaxib in PBC

Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency

Calliditas submits nefecon marketing authorisation application to the EMA

U.S. Food and Drug Administration Grants Priority Review for Nefecon of Calliditas Therapeutics AB, for Patients with IgA Nephropathy

Calliditas shares rise 10% as FDA grants priority review for Nefecon

Calliditas Therapeutics AB (publ) Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy

Calliditas Therapeutics AB (Publ) Announces Executive Appointments

Calliditas Therapeutics AB (publ) to Report Fiscal Year 2020 Final Results on Apr 27, 2021

Calliditas Therapeutics AB (Publ) Announces That the First Patient Has Been Dosed in the Global Open-Label Extension of the Phase 3 Nefigard Study

Calliditas Therapeutics AB Announces Full Enrollment of the Phase 3 NefIgArd Trial

Calliditas Therapeutics AB (publ) Announces Clinical Development Plan for Setanaxib

Calliditas Therapeutics AB (publ), Annual General Meeting, May 27, 2021

Calliditas Therapeutics AB (publ) to Report First Half, 2021 Results on Aug 19, 2021

Calliditas Therapeutics reports Q3 results

Calliditas Therapeutics AB (publ) Reports Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Calliditas Therapeutics AB (publ) Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Calliditas Therapeutics AB (publ) Announces the Last Visit of the 200Th Patient Has Taken Place in Part A of the Pivotal NeflgArd Phase 3 Study